The use of biologic therapies in uveitis

Duica, Ilona; Voinea, Liliana; Mitulescu, Costin; Istrate, Sînziana; Coman, Ioana-Cristina; Ciuluvică, Radu

doi:10.22336/rjo.2018.16

Cited by 27 publications

(29 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Infliximab is a chimeric monoclonal antibody, which neutralizes both soluble-and membrane-bound TNF-α. 3,6 It has been proven to be effective in many non-uveitic conditions such as JIA-associated uveitis, sarcoidosis, birdshot chorioretinopathy, diffuse subretinal fibrosis, and sympathetic ophthalmia. 3,10 Suhler et al have achieved clinical success in 18 out of 23 patients with Behcet's disease-associated uveitis.…”

Section: Infliximabmentioning

confidence: 99%

“…3,6 It has been proven to be effective in many non-uveitic conditions such as JIA-associated uveitis, sarcoidosis, birdshot chorioretinopathy, diffuse subretinal fibrosis, and sympathetic ophthalmia. 3,10 Suhler et al have achieved clinical success in 18 out of 23 patients with Behcet's disease-associated uveitis. 25 Markomichelakis et al have compared the efficacy of infliximab and triamcinolone in reducing ocular inflammation.…”

Section: Infliximabmentioning

confidence: 99%

“…76 Infliximab is a biological agent commonly used to treat many systemic autoimmune disease such as rheumatoid arthritis, inflammatory bowel disease, spondyloarthropathy and psoriasis. 3,6,10 The side effects of infliximab are well established. 3 A prospective, noncomparative, pilot study evaluated the effect of single intravitreal injection of infliximab (1 mg/0.05 ml) in 15 eyes with sight threatening relapsing uveitis in Behçet's disease.…”

Section: Intravitreal Injections Of Biologic Agents In Uveitismentioning

confidence: 99%

“…3,6,10 The side effects of infliximab are well established. 3 A prospective, noncomparative, pilot study evaluated the effect of single intravitreal injection of infliximab (1 mg/0.05 ml) in 15 eyes with sight threatening relapsing uveitis in Behçet's disease. A significant improvement in BCVA by day 7 was noted, which maintained during the follow up period of 30 days.…”

Section: Intravitreal Injections Of Biologic Agents In Uveitismentioning

confidence: 99%

“…2 Despite the rarity, uveitis is the cause for legal visual impairment in about one third of the population. 3,4 Uveitis can be due to infectious agent or underlying systemic disease. In some cases, the underlying cause is not detected even after tailored laboratory investigations, and they are categorized as 'idiopathic'.…”

Section: Introductıonmentioning

confidence: 99%

See 4 more Smart Citations

Biologics in uveitis: An update

Magesan

Shah²,

Biswas³

2019

IJIR

View full text Add to dashboard Cite

Uveitis is' the term used to describe inflammation of the uvea. It can be due to infective or non-infective agents. Most of the non-infectious uveitides are autoimmune or auto-inflammatory in nature, and the management of non-infective uveitis is often crucial. Advancements in biotechnology and understanding the pathophysiologies of autoimmune diseases have enabled the development of the new class of drugs named 'biologics'. These drugs act at cellular level inhibiting the actions of pro-inflammatory cytokines including tumor necrosis factor-α (TNF-α), interleukin-1, and IL-6, and B and T lymphocytes. Biologics have been proven to be less toxic and can be used in uveitic cases that are refractory to conventional therapy. Though the efficacy of biologics is based on insufficient clinical trials, majority of them indicate preferable outcomes on refractory uveitis, with remarkable promise to increase the possibility of long-term remission. In this review, we aimed to outline the ideal characteristics of each biologic drug and review the data to support the use of current and emerging biological therapies.

show abstract

Section: Infliximabmentioning

confidence: 99%